glp 1 receptor drugs Frontiers Is GLP-1 Safe for Weight

In a randomised controlled trial with over 1800 participants comparing tirzepatide to semaglutide, the tirzepatide group reported more serious adverse events (5-7% VS 3%) and higher discontinuation rates due to adverse events (6-8.5% VS 4%)

[DOI] [PubMed] [Google Scholar] 50.Grossman D.C., Bibbins-Domingo K., Curry S.J., Barry M.J., Davidson K.W., Doubeni C.A., Epling J.W., Kemper A.R., Krist A.H., Kurth A.E., et al

Limitations and future perspective The use of GLP-1RAs is predicted to increase in treating diabetes, neurological disorders, and IBD

Cureus Journal of Medical Science Please note that by doing so you agree to be added to our monthly email newsletter distribution list

Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies

Its physiological actions include stimulating glucose-dependent insulin secretion from pancreatic beta cells, suppressing glucagon release, slowing gastric emptying, and promoting satiety through central nervous system pathways